NMNH β-nicotinamide mononucleotide, reduced form

Bontac Bio-Engineering (Shenzhen) Co., Ltd., founded in 2012 and headquartered in Shenzhen's Guangming District, is a global leader in the NMN (nicotinamide mononucleotide) industry and was the first company in China to achieve industrial-scale production of coenzyme factors, including NAD, NADH, NADP, NADPH and NMN, through proprietary full-enzyme catalysis technology. Its coenzyme ingredients, alongside a broader range of active pharmaceutical ingredients, bio products, pharmaceutical excipients, enzymes, vitamins and plant extracts, serve the health, medical and beauty, green agriculture and bio-medicine industries worldwide. The company holds more than 200 domestic and international patents, the largest number of any global NMN raw-material supplier, and has built research partnerships including a joint center with Harvard Medical School. Recognized as a national-level 'Little Giant' specialized-and-innovative enterprise, Bontac has scaled coenzyme production capacity past 100 tons annually, commands an estimated 60-70% share of the NMN raw-material market, and participates in drafting multiple national group standards for NAD, NADH and NMN products, offering CMO contract manufacturing backed by an experienced R&D team and full-line production capability.